144 related articles for article (PubMed ID: 3164087)
1. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance to rhodamine 123 in Adriamycin- and daunorubicin-resistant Friend leukemia cell variants.
Tapiero H; Munck JN; Fourcade A; Lampidis TJ
Cancer Res; 1984 Dec; 44(12 Pt 1):5544-9. PubMed ID: 6498816
[TBL] [Abstract][Full Text] [Related]
3. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
4. Mutagenicity of eight anthracycline derivatives in five strains of Salmonella typhimurium.
Marzin D; Jasmin C; Maral R; Mathe G
Eur J Cancer Clin Oncol; 1983 May; 19(5):641-7. PubMed ID: 6347692
[TBL] [Abstract][Full Text] [Related]
5. Comparative uptake of adriamycin and daunorubicin in sensitive and resistant friend leukemia cells measured by flow cytometry.
Tapiero H; Fourcade A; Vaigot P; Farhi JJ
Cytometry; 1982 Mar; 2(5):298-302. PubMed ID: 6951693
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacies of aclacinomycin A by oral administration.
Tsukagoshi S; Tsuruo T; Yamori T; Iida H; Naganuma K; Sakurai Y
J Pharmacobiodyn; 1980 Oct; 3(10):532-6. PubMed ID: 6937651
[TBL] [Abstract][Full Text] [Related]
7. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
[TBL] [Abstract][Full Text] [Related]
8. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
Nishimura T; Suzuki H; Muto K; Tanaka Y; Tanaka N
J Antibiot (Tokyo); 1980 Jul; 33(7):737-43. PubMed ID: 6931828
[TBL] [Abstract][Full Text] [Related]
9. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
Tanaka N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
11. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
[TBL] [Abstract][Full Text] [Related]
12. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1989 Dec; 38(24):4467-75. PubMed ID: 2604747
[TBL] [Abstract][Full Text] [Related]
13. [Role of cell pharmacokinetics in the modulation of modalities in the administration of anthracyclines].
Tapiéro H; Boule D; Trincal G; Fourcade A
Pathol Biol (Paris); 1987 Jan; 35(1):20-6. PubMed ID: 3550608
[TBL] [Abstract][Full Text] [Related]
14. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
Tsuruo T
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
[TBL] [Abstract][Full Text] [Related]
15. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Umezawa K; Kunimoto S; Takeuchi T
Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
[TBL] [Abstract][Full Text] [Related]
16. Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo.
Tapiero H; Munck JN; Fourcade A
Drugs Exp Clin Res; 1986; 12(1-3):257-64. PubMed ID: 3460752
[TBL] [Abstract][Full Text] [Related]
17. Cellular accumulation and disposition of aclacinomycin A.
Egorin MJ; Clawson RE; Ross LA; Schlossberger NM; Bachur NR
Cancer Res; 1979 Nov; 39(11):4396-400. PubMed ID: 498071
[TBL] [Abstract][Full Text] [Related]
18. Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
Millot JM; Rasoanaivo TD; Morjani H; Manfait M
Br J Cancer; 1989 Nov; 60(5):678-84. PubMed ID: 2803945
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
